Neuromedical Systems, Inc. ("NSI") was a Suffern, New York–based medical device company founded in 1988 by Mark Rutenberg. It was a public company, listed on Nasdaq following an initial public offering in 1995 that was reported as the most successful diagnostics IPO of that year and that at one point valued the company at roughly $400 million. It operated internationally, including a wholly owned manufacturing subsidiary in Rehovot, Israel (established 1993) and operations in Europe, Asia, and Australia. It was privately funded early (about $9.65M raised, per Crunchbase/CB Insights) before going public.
Products / operations. NSI developed and marketed computer-assisted cytology screening systems. Its flagship product was the PAPNET Testing System, an FDA-cleared automated cervical cytology reader that used neural-network image analysis to flag potentially abnormal cells on Pap smear slides for cytotechnologist review. The company positioned PAPNET as a quality-control/adjunct screening tool to reduce false negatives; the product was also explored for bladder and lung cancer cytology. NSI was an operating company with a real product, not a patent-assertion entity.
Litigation posture. The tracked case data show one matter, as plaintiff only (1 plaintiff, 0 defendant): Neuromedical Systems, Inc. v. NeoPath, Inc., filed July 15, 1996 in the U.S. District Court for the Southern District of New York — not a plaintiff-friendly Texas venue. The dispute was a two-way commercial fight between the only two FDA-cleared competitors in automated Pap screening: NSI alleged NeoPath misappropriated its PAPNET technology and asserted patent infringement, unfair competition, and false advertising. NeoPath counterclaimed and separately sued NSI in the Western District of Washington (March 1997) alleging NSI infringed three NeoPath patents.
Outcome / context. A 1998 preliminary-injunction bid by NSI was denied. NSI filed for Chapter 11 bankruptcy on March 26, 1999, and the litigation was stayed. Its cytology patents and other IP were subsequently bid on by competitor AutoCyte, which shared ownership with NeoPath under a roughly $12 million asset purchase, terminating the litigation.